Skip to main content
Erschienen in: Tumor Biology 2/2014

01.02.2014 | Research Article

Increase of exostosin 1 in plasma as a potential biomarker for opisthorchiasis-associated cholangiocarcinoma

verfasst von: Jarinya Khoontawad, Nuttanan Hongsrichan, Yaovalux Chamgramol, Porntip Pinlaor, Chaisiri Wongkham, Puangrat Yongvanit, Chawalit Pairojkul, Narong Khuntikeo, Sittiruk Roytrakul, Thidarut Boonmars, Somchai Pinlaor

Erschienen in: Tumor Biology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

A proteomic-based approach was used to search for potential markers in the plasma of hamsters in which cholangiocarcinoma (CCA) was induced by Opisthorchis viverrini infection and N-nitrosodimethylamine treatment. The plasma proteins of CCA-induced hamsters were resolved by 1-D PAGE, digested by trypsin, and analyzed by LC-MS/MS. From the criteria of protein ID scores >15 and an overexpression of at least three times across all time points, 37 proteins were selected. These overexpressed proteins largely consisted of signal transduction, structural, transport, and transcriptional proteins in the order. Among the most frequently upregulated proteins, exostosin 1 (EXT1) was selected for further validation. By western blot analysis, the EXT1 expression level in the plasma of hamster CCA was significantly higher than that of controls at 1 month and thereafter. Immunohistochemistry revealed that EXT1 was expressed at vascular walls and fibroblasts at 21 days (before tumor onset) and at 2 months (early CCA) posttreatment. Its expression was also observed in bile duct cancer cells during tumor progression at 6 months posttreatment. In the human CCA tissue microarray, EXT1 immunoreactivity was found not only in vascular walls and fibroblasts but also in bile duct cancer cells and was positive in 89.7 % (61/68) of the cases. By ELISA and immunoblotting, plasma EXT1 level was significantly higher in human CCA compared to healthy controls. In conclusion, these results suggest that increased expression of EXT1 level in the plasma might be involved in CCA genesis and might be a potential biomarker of CCA.
Literatur
1.
Zurück zum Zitat Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang YY, et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci. 2010;101:579–85.PubMedCrossRef Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang YY, et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci. 2010;101:579–85.PubMedCrossRef
2.
Zurück zum Zitat Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366:1303–14.PubMedCrossRef Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366:1303–14.PubMedCrossRef
3.
Zurück zum Zitat Sriamporn S, Pisani P, Pipitgool V, Suwanrungruang K, Kamsa-ard S, Parkin DM. Prevalence of Opisthorchis viverrini infection and incidence of cholangiocarcinoma in Khon Kaen, northeast thailand. Trop Med Int Health. 2004;9:588–94.PubMedCrossRef Sriamporn S, Pisani P, Pipitgool V, Suwanrungruang K, Kamsa-ard S, Parkin DM. Prevalence of Opisthorchis viverrini infection and incidence of cholangiocarcinoma in Khon Kaen, northeast thailand. Trop Med Int Health. 2004;9:588–94.PubMedCrossRef
4.
Zurück zum Zitat Sripa B, Pairojkul C. Cholangiocarcinoma: lessons from thailand. Curr Opin Gastroenterol. 2008;24:349–56.PubMedCrossRef Sripa B, Pairojkul C. Cholangiocarcinoma: lessons from thailand. Curr Opin Gastroenterol. 2008;24:349–56.PubMedCrossRef
6.
Zurück zum Zitat Alvaro D. Serum and bile biomarkers for cholangiocarcinoma. Curr Opin Gastroenterol. 2009;25:279–84.PubMedCrossRef Alvaro D. Serum and bile biomarkers for cholangiocarcinoma. Curr Opin Gastroenterol. 2009;25:279–84.PubMedCrossRef
7.
Zurück zum Zitat Thamavit W, Bhamarapravati N, Sahaphong S, Vajrasthira S, Angsubhakorn S. Effects of dimethylnitrosamine on induction of cholangiocarcinoma in Opisthorchis viverrini-infected syrian golden hamsters. Cancer Res. 1978;38:4634–9.PubMed Thamavit W, Bhamarapravati N, Sahaphong S, Vajrasthira S, Angsubhakorn S. Effects of dimethylnitrosamine on induction of cholangiocarcinoma in Opisthorchis viverrini-infected syrian golden hamsters. Cancer Res. 1978;38:4634–9.PubMed
8.
Zurück zum Zitat Prakobwong S, Yongvanit P, Hiraku Y, Pairojkul C, Sithithaworn P, Pinlaor P, et al. Involvement of mmp-9 in peribiliary fibrosis and cholangiocarcinogenesis via rac1-dependent DNA damage in a hamster model. Int J Cancer. 2010;127:2576–87.PubMedCrossRef Prakobwong S, Yongvanit P, Hiraku Y, Pairojkul C, Sithithaworn P, Pinlaor P, et al. Involvement of mmp-9 in peribiliary fibrosis and cholangiocarcinogenesis via rac1-dependent DNA damage in a hamster model. Int J Cancer. 2010;127:2576–87.PubMedCrossRef
9.
Zurück zum Zitat Sripa B, Mairiang E, Thinkhamrop B, Laha T, Kaewkes S, Sithithaworn P, et al. Advanced periductal fibrosis from infection with the carcinogenic human liver fluke Opisthorchis viverrini correlates with elevated levels of interleukin-6. Hepatology. 2009;50:1273–81.PubMedCentralPubMedCrossRef Sripa B, Mairiang E, Thinkhamrop B, Laha T, Kaewkes S, Sithithaworn P, et al. Advanced periductal fibrosis from infection with the carcinogenic human liver fluke Opisthorchis viverrini correlates with elevated levels of interleukin-6. Hepatology. 2009;50:1273–81.PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Juan HF, Chen JH, Hsu WT, Huang SC, Chen ST, Yi-Chung Lin J, et al. Identification of tumor-associated plasma biomarkers using proteomic techniques: from mouse to human. Proteomics. 2004;4:2766–75.PubMedCrossRef Juan HF, Chen JH, Hsu WT, Huang SC, Chen ST, Yi-Chung Lin J, et al. Identification of tumor-associated plasma biomarkers using proteomic techniques: from mouse to human. Proteomics. 2004;4:2766–75.PubMedCrossRef
11.
Zurück zum Zitat Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002;1:845–67.PubMedCrossRef Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002;1:845–67.PubMedCrossRef
12.
Zurück zum Zitat Khoontawad J, Laothong U, Roytrakul S, Pinlaor P, Mulvenna J, Wongkham C, et al. Proteomic identification of plasma protein tyrosine phosphatase alpha and fibronectin associated with liver fluke, Opisthorchis viverrini, infection. PLoS One. 2012;7:e45460.PubMedCentralPubMedCrossRef Khoontawad J, Laothong U, Roytrakul S, Pinlaor P, Mulvenna J, Wongkham C, et al. Proteomic identification of plasma protein tyrosine phosphatase alpha and fibronectin associated with liver fluke, Opisthorchis viverrini, infection. PLoS One. 2012;7:e45460.PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Guo J, Wang W, Liao P, Lou W, Ji Y, Zhang C, et al. Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis. Cancer Sci. 2009;100:2292–301.PubMedCrossRef Guo J, Wang W, Liao P, Lou W, Ji Y, Zhang C, et al. Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis. Cancer Sci. 2009;100:2292–301.PubMedCrossRef
14.
Zurück zum Zitat Yonglitthipagon P, Pairojkul C, Chamgramol Y, Mulvenna J, Sripa B. Up-regulation of annexin a2 in cholangiocarcinoma caused by Opisthorchis viverrini and its implication as a prognostic marker. Int J Parasitol. 2010;40:1203–12.PubMedCentralPubMedCrossRef Yonglitthipagon P, Pairojkul C, Chamgramol Y, Mulvenna J, Sripa B. Up-regulation of annexin a2 in cholangiocarcinoma caused by Opisthorchis viverrini and its implication as a prognostic marker. Int J Parasitol. 2010;40:1203–12.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Lin X, Gan L, Klein WH, Wells D. Expression and functional analysis of mouse ext1, a homolog of the human multiple exostoses type 1 gene. Biochem Biophys Res Commun. 1998;248:738–43.PubMedCrossRef Lin X, Gan L, Klein WH, Wells D. Expression and functional analysis of mouse ext1, a homolog of the human multiple exostoses type 1 gene. Biochem Biophys Res Commun. 1998;248:738–43.PubMedCrossRef
16.
Zurück zum Zitat Lin X, Wells D. Isolation of the mouse cdna homologous to the human ext1 gene responsible for hereditary multiple exostoses. DNA Seq. 1997;7:199–202.PubMed Lin X, Wells D. Isolation of the mouse cdna homologous to the human ext1 gene responsible for hereditary multiple exostoses. DNA Seq. 1997;7:199–202.PubMed
17.
Zurück zum Zitat de Andrea CE, Hogendoorn PC. Epiphyseal growth plate and secondary peripheral chondrosarcoma: the neighbours matter. J Pathol. 2012;226:219–28.PubMedCrossRef de Andrea CE, Hogendoorn PC. Epiphyseal growth plate and secondary peripheral chondrosarcoma: the neighbours matter. J Pathol. 2012;226:219–28.PubMedCrossRef
18.
Zurück zum Zitat Cook A, Raskind W, Blanton SH, Pauli RM, Gregg RG, Francomano CA, et al. Genetic heterogeneity in families with hereditary multiple exostoses. Am J Hum Genet. 1993;53:71–9.PubMedCentralPubMed Cook A, Raskind W, Blanton SH, Pauli RM, Gregg RG, Francomano CA, et al. Genetic heterogeneity in families with hereditary multiple exostoses. Am J Hum Genet. 1993;53:71–9.PubMedCentralPubMed
19.
Zurück zum Zitat Bernard MA, Hall CE, Hogue DA, Cole WG, Scott A, Snuggs MB, et al. Diminished levels of the putative tumor suppressor proteins ext1 and ext2 in exostosis chondrocytes. Cell Motil Cytoskeleton. 2001;48:149–62.PubMedCrossRef Bernard MA, Hall CE, Hogue DA, Cole WG, Scott A, Snuggs MB, et al. Diminished levels of the putative tumor suppressor proteins ext1 and ext2 in exostosis chondrocytes. Cell Motil Cytoskeleton. 2001;48:149–62.PubMedCrossRef
20.
Zurück zum Zitat Osterholm C, Barczyk MM, Busse M, Gronning M, Reed RK, Kusche-Gullberg M. Mutation in the heparan sulfate biosynthesis enzyme ext1 influences growth factor signaling and fibroblast interactions with the extracellular matrix. J Biol Chem. 2009;284:34935–43.PubMedCrossRef Osterholm C, Barczyk MM, Busse M, Gronning M, Reed RK, Kusche-Gullberg M. Mutation in the heparan sulfate biosynthesis enzyme ext1 influences growth factor signaling and fibroblast interactions with the extracellular matrix. J Biol Chem. 2009;284:34935–43.PubMedCrossRef
21.
Zurück zum Zitat Zak BM, Crawford BE, Esko JD. Hereditary multiple exostoses and heparan sulfate polymerization. Biochim Biophys Acta. 2002;1573:346–55.PubMedCrossRef Zak BM, Crawford BE, Esko JD. Hereditary multiple exostoses and heparan sulfate polymerization. Biochim Biophys Acta. 2002;1573:346–55.PubMedCrossRef
23.
Zurück zum Zitat Schmale GA, Conrad 3rd EU, Raskind WH. The natural history of hereditary multiple exostoses. J Bone Joint Surg Am. 1994;76:986–92.PubMed Schmale GA, Conrad 3rd EU, Raskind WH. The natural history of hereditary multiple exostoses. J Bone Joint Surg Am. 1994;76:986–92.PubMed
24.
Zurück zum Zitat Jhandier MN, Kruglov EA, Lavoie EG, Sevigny J, Dranoff JA. Portal fibroblasts regulate the proliferation of bile duct epithelia via expression of ntpdase2. J Biol Chem. 2005;280:22986–92.PubMedCrossRef Jhandier MN, Kruglov EA, Lavoie EG, Sevigny J, Dranoff JA. Portal fibroblasts regulate the proliferation of bile duct epithelia via expression of ntpdase2. J Biol Chem. 2005;280:22986–92.PubMedCrossRef
25.
Zurück zum Zitat Juttijudata P, Chiemchaisri C, Palavatana C, Churnratanakul S. Causes of cholestasis in Thailand. A study of 276 consecutive patients. Am J Surg. 1984;147:360–6.PubMedCrossRef Juttijudata P, Chiemchaisri C, Palavatana C, Churnratanakul S. Causes of cholestasis in Thailand. A study of 276 consecutive patients. Am J Surg. 1984;147:360–6.PubMedCrossRef
26.
Zurück zum Zitat Farazi PA, Zeisberg M, Glickman J, Zhang Y, Kalluri R, DePinho RA. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res. 2006;66:6622–7.PubMedCrossRef Farazi PA, Zeisberg M, Glickman J, Zhang Y, Kalluri R, DePinho RA. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res. 2006;66:6622–7.PubMedCrossRef
27.
Zurück zum Zitat Ong CK, Subimerb C, Pairojkul C, Wongkham S, Cutcutache I, Yu W, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet. 2012;44:690–3.PubMedCrossRef Ong CK, Subimerb C, Pairojkul C, Wongkham S, Cutcutache I, Yu W, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet. 2012;44:690–3.PubMedCrossRef
28.
Zurück zum Zitat Sirica AE. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2012;9:44–54.CrossRef Sirica AE. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2012;9:44–54.CrossRef
29.
Zurück zum Zitat McCormick C, Leduc Y, Martindale D, Mattison K, Esford LE, Dyer AP, et al. The putative tumour suppressor ext1 alters the expression of cell-surface heparan sulfate. Nat Genet. 1998;19:158–61.PubMedCrossRef McCormick C, Leduc Y, Martindale D, Mattison K, Esford LE, Dyer AP, et al. The putative tumour suppressor ext1 alters the expression of cell-surface heparan sulfate. Nat Genet. 1998;19:158–61.PubMedCrossRef
30.
Zurück zum Zitat Lind T, Tufaro F, McCormick C, Lindahl U, Lidholt K. The putative tumor suppressors ext1 and ext2 are glycosyltransferases required for the biosynthesis of heparan sulfate. J Biol Chem. 1998;273:26265–8.PubMedCrossRef Lind T, Tufaro F, McCormick C, Lindahl U, Lidholt K. The putative tumor suppressors ext1 and ext2 are glycosyltransferases required for the biosynthesis of heparan sulfate. J Biol Chem. 1998;273:26265–8.PubMedCrossRef
31.
Zurück zum Zitat Tatrai P, Egedi K, Somoracz A, van Kuppevelt TH, Ten Dam G, Lyon M, et al. Quantitative and qualitative alterations of heparan sulfate in fibrogenic liver diseases and hepatocellular cancer. J Histochem Cytochem. 2010;58:429–41.PubMedCrossRef Tatrai P, Egedi K, Somoracz A, van Kuppevelt TH, Ten Dam G, Lyon M, et al. Quantitative and qualitative alterations of heparan sulfate in fibrogenic liver diseases and hepatocellular cancer. J Histochem Cytochem. 2010;58:429–41.PubMedCrossRef
32.
Zurück zum Zitat Koo CY, Sen YP, Bay BH, Yip GW. Targeting heparan sulfate proteoglycans in breast cancer treatment. Recent Pat Anticancer Drug Discov. 2008;3:151–8.PubMedCrossRef Koo CY, Sen YP, Bay BH, Yip GW. Targeting heparan sulfate proteoglycans in breast cancer treatment. Recent Pat Anticancer Drug Discov. 2008;3:151–8.PubMedCrossRef
33.
Zurück zum Zitat Davies EJ, Blackhall FH, Shanks JH, David G, McGown AT, Swindell R, et al. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2004;10:5178–86.CrossRef Davies EJ, Blackhall FH, Shanks JH, David G, McGown AT, Swindell R, et al. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2004;10:5178–86.CrossRef
35.
Zurück zum Zitat Gabbiani G, Ryan GB, Majne G. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia. 1971;27:549–50.PubMedCrossRef Gabbiani G, Ryan GB, Majne G. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia. 1971;27:549–50.PubMedCrossRef
Metadaten
Titel
Increase of exostosin 1 in plasma as a potential biomarker for opisthorchiasis-associated cholangiocarcinoma
verfasst von
Jarinya Khoontawad
Nuttanan Hongsrichan
Yaovalux Chamgramol
Porntip Pinlaor
Chaisiri Wongkham
Puangrat Yongvanit
Chawalit Pairojkul
Narong Khuntikeo
Sittiruk Roytrakul
Thidarut Boonmars
Somchai Pinlaor
Publikationsdatum
01.02.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 2/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1137-9

Weitere Artikel der Ausgabe 2/2014

Tumor Biology 2/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.